Literature DB >> 2935251

Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.

C W Young, V Raymond.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2935251

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

Authors:  Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

3.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

4.  Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study.

Authors:  G F Vile; C C Winterbourn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI.

Authors:  D Piwnica-Worms; M L Chiu; J F Kronauge
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

Authors:  J Cummings; D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Authors:  R D Olson; P S Mushlin; D E Brenner; S Fleischer; B J Cusack; B K Chang; R J Boucek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.